Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer - Wikidata - awgldk - TriplyDB

Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer

Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer

http://www.wikidata.org/entity/Q33740707

about

Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy Associations between EGFR gene polymorphisms and susceptibility to glioma: a systematic review and meta-analysis from GWAS and case-control studies.Non-invasive diagnostic platforms in management of non-small cell lung cancer: opportunities and challenges.Identification of Clinically Approved Drugs Indacaterol and Canagliflozin for Repurposing to Treat Epidermal Growth Factor Tyrosine Kinase Inhibitor-Resistant Lung Cancer.Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation.SKLB188 inhibits the growth of head and neck squamous cell carcinoma by suppressing EGFR signalling.The emerging treatment landscape of advanced non-small cell lung cancer.Design, synthesis, and screening of ortho-amino thiophene carboxamide derivatives on hepatocellular carcinomaas VEGFR-2Inhibitors

P2860

Q38598893-8AF54AD0-1F77-4C0C-BFA7-75A27F702CA1 Q45345647-E3451DC5-706E-4839-9C8E-22ED43B84A04 Q45891469-93121508-B98A-4195-A207-E3DC1F32131E Q47100541-39A894B6-5E72-4676-9293-195185C28FF7 Q47814631-057FDCFB-029F-4BE5-8E4B-0AD294CEF999 Q47854833-C47307F5-4AC0-4F2D-BB42-47FD363033DE Q55342455-6B54502B-0556-4C2B-B575-13B6E434A606 Q58759036-6AE93EE6-CFA4-47F2-81B7-7E46C25B75D9

P2860

Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer

http://www.wikidata.org/entity/Q33740707

description

2017 nî lūn-bûn

@nan

2017 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Third-Generation Tyrosine Kina ...... in Non-Small Cell Lung Cancer

@ast

Third-Generation Tyrosine Kina ...... in Non-Small Cell Lung Cancer

@en

type

label

Third-Generation Tyrosine Kina ...... in Non-Small Cell Lung Cancer

@ast

Third-Generation Tyrosine Kina ...... in Non-Small Cell Lung Cancer

@en

prefLabel

Third-Generation Tyrosine Kina ...... in Non-Small Cell Lung Cancer

@ast

Third-Generation Tyrosine Kina ...... in Non-Small Cell Lung Cancer

@en

P1433

Q33740707-0BB4781B-52D6-48DD-85D1-616637647127

P1476

Q33740707-0226867A-1ACB-4F52-AE24-FA224CD372DB

P2093

Q33740707-882BDACB-4D29-47B0-AA9D-79CF4723DE82

Q33740707-ABCD544A-A3B4-4F7B-92A5-85E1757A4B58

Q33740707-D0A43D49-161C-4911-BE9E-2DDDFEC6E71E

Q33740707-FD17A567-5D3B-4371-A4E3-2385ED9BBCE2

P2860

Q33740707-046CC1F4-1690-4837-87D2-CACB55B0DD09

Q33740707-0B839324-7711-4957-81BE-D457ADD04B59

Q33740707-0D3FD6BD-8E43-4CAE-A892-8599792EAA2F

Q33740707-10CE63E2-63EC-496F-AAB0-1EE69A657607

Q33740707-114EDF9D-33F0-4647-8743-8B81C9A7DFA9

Q33740707-120A6C45-C851-4725-85B6-A86ABF17E695

Q33740707-1345C25D-5D06-4D58-887A-70A4663C72B9

Q33740707-1356F6FE-50F8-4789-82AA-4D52878ED3E4

Q33740707-1808F277-2EEC-456A-AEB6-D055F8BCCA89

Q33740707-1B63D809-A315-488C-88DA-263476BC4BBD

P304

Q33740707-5F092454-B420-4A6B-9F7A-136EED044B8C

P31

Q33740707-DB756FC3-4AF9-4753-B5C1-93030B94B6F4

P356

Q33740707-94DB54B3-2E6C-42EE-AA27-3BCBDB217BDA

P478

Q33740707-8978B589-6F90-4809-89C5-20C2315ACA69

P577

Q33740707-EA7AC84B-646D-459B-9511-CB0A19A83006

P698

Q33740707-7B022248-3072-4E1F-AB06-90ADAE9673DD

P932

Q33740707-785A9E87-94C7-4E3E-8916-878B5FFA5DBB

P356

FONC.2017.00113

P1433

Frontiers in Oncology

P1476

Third-Generation Tyrosine Kina ...... in Non-Small Cell Lung Cancer

@en

P2093

Grainne M O'Kane

http://www.w3.org/2001/XMLSchema#string

Mark David Vincent

http://www.w3.org/2001/XMLSchema#string

Natasha B Leighl

http://www.w3.org/2001/XMLSchema#string

Tristan A Barnes

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

P304

113

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FONC.2017.00113

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28620581

http://www.w3.org/2001/XMLSchema#string

P932

5449484

http://www.w3.org/2001/XMLSchema#string